Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis

Objective To assess the effects of corticosteroids on mortality in patients with severe sepsis and septic shock. Data sources Randomised and quasi-randomised trials of corticosteroids versus placebo (or supportive treatment alone) retrieved from the Cochrane infectious diseases group's trials register, the Cochrane central register of controlled trials, Medline, Embase, and LILACS. Review method Two pairs of reviewers agreed on eligibility of trials. One reviewer entered data on to the computer and four reviewers checked them. We obtained some missing data from authors of trials and assessed methodological quality of trials. Results 16/23 trials (n=2063) were selected. Corticosteroids; did not change 28 day mortality (15 trials, n=2022; relative risk 0.92, 95% confidence interval 0.75 to 1.14) or hospital mortality (13 trials, n=1418; 0.89, 0.71 to 1.11). There was significant heterogeneity Subgroup analysis on long courses (greater than or equal to5 days) with low dose (less than or equal to300 mg hydrocortisone or equivalent) corticosteroids showed no more heterogeneity The relative risk for mortality was 0.80 at 28 days (five trials, n=465; 0.67 to 0.95) and 0.83 at hospital discharge (five trials, n=465, 0.71 to 0.97). Use of corticosteroids reduced mortality in intensive care units (four trials, n=425, 0.83, 0.70 to 0.97), increased shock reversal at 7 days (four trials, n=425; 1.60, 1.27 to 2.03) and 28 days (four trials, n=425, 1.26, 1.04 to 1.52) without inducing side effects. Conclusions For all trials, regardless of duration of, treatment and dose, use of corticosteroids did not significantly affect mortality. With long courses of low doses of corticosteroids, however, mortality at 28 days and hospital morality was reduced.